Overall survival results from a phase III trial of trifluridine/tipiracil (FTD/TPI) vs placebo in patients (Pts) with metastatic gastric cancer refractory to standard therapies (TAGS)

Authors :: K. Shitara
J. Tabernero
M. Dvorkin
W. Mansoor
H.-T. Arkenau
A. Prokharau
M. Alsina
M. Ghidini
C. Faustino
V. Gorbunova
E. Zhavrid
K. Nishikawa
A. Hosokawa
D. Ganea
Ş. Yalçın
K. Fujitani
G. Beretta
R. Winkler
T. Doi
D.H. Ilson
Source :: Annals of Oncology. 29:ix55
Publication Year :: 2018
Publisher :: Elsevier BV, 2018.

Full Text Access

Tools